Medtronic Faces Antitrust Hit While Betting On Stealth AXiS Growth

Simply Wall St

Sun, February 15, 2026 at 5:10 PM GMT+9 3 min read

In this article:

MDT

-1.38%

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Medtronic (NYSE:MDT) recently lost a major antitrust lawsuit that resulted in a multi hundred million dollar damages award against the company.

In a separate development, Medtronic announced FDA clearance for its Stealth AXiS surgical system, a next generation spine surgery platform.

The Stealth AXiS system integrates planning, navigation, robotics and real time patient alignment tracking for spine procedures.

Medtronic is a large medical technology company with a broad portfolio across cardiac, neurology, diabetes and surgical devices. The antitrust loss adds a legal and financial overhang at the same time the company is expanding its presence in advanced surgical systems. For investors, these parallel storylines relate to both risk management and product development in a key segment of the medical device industry.

Looking ahead, the size of the damages award and any follow on legal actions will be important for understanding potential cash flow and balance sheet impact. At the same time, early adoption and clinical use of Stealth AXiS could help indicate how Medtronic’s integrated spine platform fits into hospitals’ equipment budgets and surgeons’ workflow decisions.

Stay updated on the most important news stories for Medtronic by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Medtronic.

NYSE:MDT 1-Year Stock Price Chart

Is Medtronic’s balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.

Investor Checklist

Quick Assessment

**⚖️ Price vs Analyst Target**: At US$99.49 versus the US$112.00 analyst target, the price sits about 11% below consensus, close to the fair band defined by the US$100.00 to US$121.00 range.

**⚖️ Simply Wall St Valuation**: Shares are described as trading close to estimated fair value, so the lawsuit and product launch sit against a fairly priced starting point.

**✅ Recent Momentum**: A 30 day return of 2.8% shows modest positive price momentum into this legal setback and product rollout.

There is only one way to know the right time to buy, sell or hold Medtronic. Head to Simply Wall St’s company report for the latest analysis of Medtronic’s Fair Value.

Key Considerations

📊 Balance the antitrust damages overhang with the potential contribution from the Stealth AXiS spine platform to Medtronic's extensive device portfolio.

📊 Watch how the US$99.49 price tracks against the US$112.00 target, the 26.8x P/E relative to the Medical Equipment average, and early hospital uptake of Stealth AXiS.

⚠️ The key risk to monitor is how the multi hundred million dollar antitrust award and any related actions affect cash flows and debt metrics over time.

 






Story continues  

Dig Deeper

For the full picture including more risks and rewards, check out the complete Medtronic analysis. Alternatively, you can check out the community page for Medtronic to see how other investors believe this latest news will impact the company’s narrative.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include MDT.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info